EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IL-18 revives dysfunctional CAR-T cells

Yan-Ruide Li, Yichen Zhu, Lili Yang

Trends in Cancer · 2025

DOI: 10.1016/j.trecan.2025.06.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Trends in Cancer, 2025. Verfasst von Yan-Ruide Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengi…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Interleukin-18, Lymphoma, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of California Los Angeles.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IL-18-armored chimeric antigen receptor (CAR)-engineered T (18.CAR-T) cells have demonstrated enhanced antitumor efficacy in lymphoma patients refractory to conventional CAR-T therapy. Unraveling the mechanisms behind this potent enhancement and mitigating associated toxicities could unlock a new era of next-generation CAR-T therapies with superior effectiveness and broader clinical impact.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveInterleukin-18LymphomaReceptors, Chimeric AntigenT-LymphocytesAnimalsHumansReceptors, Antigen, T-Cell

Stichwörter der Autor:innen

CAR-T dysfunctioncancer therapychimeric antigen receptor (CAR)interleukin-18 (IL-18)superior antitumor efficacy

Substanzen

Interleukin-18Receptors, Antigen, T-CellReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095,…

Förderung

  • University of California Los Angeles

Zitieren

APA

Li, Y. R., Zhu, Y., & Yang, L. (2025). IL-18 revives dysfunctional CAR-T cells. Trends in Cancer. https://doi.org/10.1016/j.trecan.2025.06.008

Vancouver

Li YR, Zhu Y, Yang L. IL-18 revives dysfunctional CAR-T cells. Trends in Cancer. 2025. doi:10.1016/j.trecan.2025.06.008

BibTeX
@article{Li2025,
  author = {Li, Yan-Ruide and Zhu, Yichen and Yang, Lili},
  title = {IL-18 revives dysfunctional CAR-T cells},
  journal = {Trends in Cancer},
  year = {2025},
  doi = {10.1016/j.trecan.2025.06.008}
}
Kostenlos starten →